Abstract
Background Cardiovascular diseases(CVD) increase mortality risk from coronavirus infection(COVID-19), but there are concerns that the pandemic has affected supply and demand of acute cardiovascular care. We estimated excess mortality in specific CVDs, both “direct”, through infection, and “indirect”, through changes in healthcare.
Methods We used population-based electronic health records from 3,862,012 individuals in England to estimate pre- and post-COVID-19 mortality risk(“direct” effect) for people with incident and prevalent CVD. We incorporated: (i)pre-COVID-19 risk by age, sex and comorbidities, (ii)estimated population COVID-19 prevalence, and (iii)estimated relative impact of COVID-19 on mortality(relative risk, RR: 1.5, 2.0 and 3.0). For “indirect” effects, we analysed weekly mortality and emergency department data for England/Wales and monthly hospital data from England(n=2), China(n=5) and Italy(n=1) for CVD referral, diagnosis and treatment until 1 May 2020.
Findings CVD service activity decreased by 60-100% compared with pre-pandemic levels in eight hospitals across China, Italy and England during the pandemic. In China, activity remained below pre-COVID-19 levels for 2-3 months even after easing lockdown, and is still reduced in Italy and England. Mortality data suggest indirect effects on CVD will be delayed rather than contemporaneous(peak RR 1.4). For total CVD(incident and prevalent), at 10% population COVID-19 rate, we estimated direct impact of 31,205 and 62,410 excess deaths in England at RR 1.5 and 2.0 respectively, and indirect effect of 49932 to 99865 excess deaths.
Interpretation Supply and demand for CVD services have dramatically reduced across countries with potential for substantial, but avoidable, excess mortality during and after the COVID-19 pandemic.
Funding NIHR, HDR UK, Astra Zeneca
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
AB has received research funding from NIHR, UKRI, British Medical Association and Astra Zeneca. BW and HH are funded by the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre. HH is supported by Health Data Research UK (HDR-UK; grant no LOND1), which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation, and Wellcome Trust. AB, SC, SD, HH is also supported by the BigData@Heart Consortium, funded by the Innovative Medicines Initiative-2 joint undertaking under grant agreement no 116074. This joint undertaking receives support from the EU Horizon 2020 research and innovation programme and European Federation of Pharmaceutical Industries and Associations. AMS is supported by the British Heart Foundation (CH/1999001/11735), the NIHR Biomedical Research Centre at Guys & St Thomas NHS Foundation Trust and Kings College London (IS-BRC-1215-20006), and the Fondation Leducq. KK is supported by NIHR ARC East Midlands. BW is supported by the NIHR University College London Hospitals Biomedical Research Centre. HW is supported by Medical Research Council and Health Data Research UK Grant (MR/S004149/1), Industrial Strategy Challenge Grant (MC_PC_18029) and Wellcome Institutional Translation Partnership Award (PIII054). MN is supported by a Wellcome Trust Investigator in Science award (207511/Z/17/Z). DB is supported by the NIHR (CL-2016-17-001).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Independent Scientific Advisory Committee of the CPRD(20_074R) under Section 251(NHS Social Care Act 2006) of the UK Medicines and Healthcare products Regulatory Agency. Hospital data was obtained with approval of the relevant hospital institutional review boards.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
There are no data available in relation to this manuscript.
